CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Michael Mahoney

Chairman, President & Chief Executive Officer, Boston Scientific

Search every verified Michael Mahoney interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Michael Mahoney, Chairman, President, and CEO of Boston Scientific, discussed the company's revised financial guidance during its Q2 2026 earnings call. He stated that the company now expects full-year 2026 organic revenue growth of 5 to 6% and adjusted EPS of $3.28 to $3.32, representing growth of 7 to 8%. Mahoney characterized the update as "not the outcome we planned," attributing the revision to quickly evolving market conditions that have made forecasting challenging. He noted that the guidance reduction is concentrated in two areas: the Watchman device, where he said the US market has slowed sharply, and electrophysiology (EP), where he expects competitive launches to impact performance in the second half of 2026 and into the first half of 2027. Mahoney expressed confidence in the Watchman therapy, calling it the best treatment for patients who cannot take oral anti-coagulation, but stated the company is not assuming improved growth for the product in 2027 until market dynamics change. He also discussed the EP business, saying the company has lost some US market share but continues to perform well in Europe and Asia Pacific. He indicated that Boston Scientific expects to launch its next-generation Ultra and ICE devices in the first half of 2027, with the business expected to strengthen in the second half of 2027 and into 2028. Mahoney said the company's revenue and EPS growth profile should improve meaningfully in 2028, supported by key catalysts, while the company remains focused on execution and delivering its 2026 guidance.

Recent appearances

Notable quotes

“It's frustrating because we've had a hard time with our stock price lately. I'm convinced that there are long-term investors, but I don't know if anybody really is a long-term investor anymore. It's kind of quarter by quarter.”

“We spend about 10% internally on R&D, about $2.2 billion this year. We lead the league in clinical science, spending about 35% of that on clinical studies. Our venture portfolio is the largest in medtech; we've invested over $2.2 billion in it since 2013, and about a third of the companies we've acquired have come from that portfolio.”

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →